Schröder K, Agrawal R, Völler H, Schlief R, Schröder R
Klinikum Steglitz, University Berlin, Dept. of Cardiology, Germany.
Int J Card Imaging. 1994 Mar;10(1):45-51. doi: 10.1007/BF01151580.
Recent studies have shown that the saccharide based echocardiographic contrast agent SH U 508 A opacifies the left ventricle after i.v. injection, thus possibly improving endocardial border definition. This study was performed to determine whether SH U 508 A can enhance the wall motion analysis in suboptimal echocardiographic images at rest and following pharmacological stress. Ten male patients (mean 58 years) exhibiting > or = 30% endocardial border dropout were examined prior to a diagnostic left heart catheterization. Five patients were stressed with Dobutamine, 5 with Dipyridamole. The wall motion was assessed visually (qualitatively) as well as computer-aided (quantitatively). The concordance between left ventricular angiography as 'gold standard' and resting echocardiography regarding the wall motion analysis was significantly improved from 64.5% to 90.3% following the injection of SH U 508 A (p < 0.05). A delineation score (0 = not delineated, 1 = delineated) of 12 individual wall segments was used. The mean delineation score at baseline was 6.1 +/- 1.4 at rest and 6.6 +/- 1.9 during stress. SH U 508 A significantly (p < 0.01) increased the score to 9.6 +/- 1.9 and 10.3 +/- 1.7, respectively. The intraobserver variability for assessing the delineation score was significantly (p < 0.04) improved by SH U 508 A. SH U 508 A, however, did not improve the quantitative assessment of the left ventricular function. Only 40% of the patients could be analyzed following SH U 508 A injection. No severe adverse reactions were seen. SH U 508 A led to a significant, clinically important, improvement in the interpretation of stress echocardiograms in patients with inconclusive routine echocardiograms.
近期研究表明,基于糖类的超声心动图造影剂SH U 508 A经静脉注射后可使左心室显影,从而可能改善心内膜边界清晰度。本研究旨在确定SH U 508 A能否增强静息状态及药物负荷状态下超声心动图图像欠佳时的室壁运动分析。在进行诊断性左心导管检查前,对10例男性患者(平均年龄58岁)进行了检查,这些患者的心内膜边界缺失≥30%。5例患者使用多巴酚丁胺负荷,5例患者使用双嘧达莫负荷。通过视觉(定性)和计算机辅助(定量)评估室壁运动。以左心室造影作为“金标准”,注射SH U 508 A后,静息超声心动图在室壁运动分析方面与左心室造影的一致性从64.5%显著提高至90.3%(p<0.05)。采用12个独立室壁节段的清晰评分(0=未清晰显示,1=清晰显示)。静息时基线平均清晰评分为6.1±1.4,负荷时为6.6±1.9。SH U 508 A分别使评分显著(p<0.01)提高至9.6±1.9和10.3±1.7。SH U 508 A显著(p<0.04)改善了观察者间评估清晰评分的变异性。然而,SH U 508 A并未改善左心室功能的定量评估。注射SH U 508 A后仅40%的患者可进行分析。未观察到严重不良反应。对于常规超声心动图结果不明确的患者,SH U 508 A显著且在临床上显著改善了负荷超声心动图的解读。